WhiteBook2_Part2 - 40

Appendix
Assess burden of disease and its
determinants
Develop new capacities to
reduce burden
Develop new capacities to
reduce burden
Improve performance of existing
capacities to reduce burden
Improve performance of existing
capacities to reduce burden
Epidemiology
Diagnosis
Health care
quality, access,
and evaluation
Metabolism
Polish Society of Gastroenterology
Diagnosis
Portuguese Society of Gastroenterology
Assess burden of disease and its
determinants
Assess burden of disease and its
determinants
Improve performance of existing
capacities to reduce burden
Mortality
Diagnosis
All diseases of the digestive
system (K20-K93)
Epidemiology
Diseases of pancreas (K85K86,
K87.1)
Viral hepatitis (B15-B19)
Malignant neoplasms of
digestive organs (C15-C26)
Romanian Society of Gastroenterology and Hepatology
Assess burden of disease and its
determinants
Drug therapy
Assess burden of disease and its
determinants
Assess burden of disease and its
determinants
Develop new capacities to
reduce burden
Improve performance of existing
capacities to reduce burden
SAHGEED (Algeria)
Assess burden of disease and its
determinants
Assess burden of disease and its
determinants
Assess burden of disease and its
determinants
SIGE/AIGO (Italy)
Assess burden of disease and its
determinants
Develop new capacities to
reduce burden
White Book 2: Part 2
Health care
quality, access,
and evaluation
Health care
quality, access,
and evaluation
Prevention and
control
Genetics
Crohn's disease and
ulcerative colitis (K50-K51)
All diseases of the digestive
system (K20-K93)
Other diseases of the
digestive system (K90.1K93)
Diseases
of pancreas (K85K86,
K87.1)
Malignant neoplasms of
digestive organs (C15-C26)
Aetiology
Drug therapy
Drug therapy
Economics e.g.
cost analysis
Drug therapy
Other diseases of liver (K71K77)
Crohn's
disease and
ulcerative colitis (K50-K51)
Other diseases of liver (K71K77)
All
diseases of the digestive
system (K20-K93)
Other diseases of liver (K71K77)
The
conducted research
concerns endoscopy in the
prevention
Pancreatic cancer is increasing
Screening of HCV and HBV
The burden of digestive
cancers, has been one top
priority
personalized medicine, artificial
intelligence
artificial intelligence, primary
prevention-screening
neurogastroenterology,
microbiotics, fecal
transplantation
diagnosis/genetics/prevention
and control
biomarkers/genomics/
personalized medicine
/prevention /control
Budd Chiari Syndrome ,
Aetiological workup
Anti TNF alpha therapy with
biosimilars
Efficacy of generics in Hep C
Digestive diseases are under
diagnosed and underweighted
NAFLD/NASH is expected to
become the main liver disorder
37
Crohn's disease and
ulcerative colitis (K50-K51)
Other diseases of
gallbladder and biliary tract
(K81-K83, K87.0)
Irritable bowel syndrome
(K58)
Not applicable
Prospective population-based
IBD cohort
Primary sclerosing cholangitis,
cholangiocarcinoma
Patient and healthcare
education
Metabolic implications of
bariatric therapy
WhiteBook2_Part2

Table of Contents for the Digital Edition of WhiteBook2_Part2
